01-Aug-2022 | Facts and Factors
According to Facts and Factors, the global blood plasma fractionation market was worth USD 28.1 billion in 2021 and is estimated to grow to USD 39.2 billion by 2028, with a compound annual growth rate (CAGR) of approximately 5.70% over the forecast period. The report analyzes the Blood Plasma Fractionation Market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the Blood Plasma Fractionation Market.
Products made from blood plasma fractionation that have therapeutic properties are used to treat a variety of illnesses. For instance, haemophilia is treated and prevented using coagulation factor VIII, a plasma derivative. It is used to stop excessive blood loss during surgery. Immune deficiencies, both primary and secondary, are treated using immunoglobulins. One of the main factors driving the growth of the blood plasma fractionation market is the rise in the number of elderly people around the world, who are more prone to rare disorders that call for the usage of plasma derivatives. Owing to the rise in demand for Blood Plasma Fractionation, the Global Blood Plasma FractionationMarketis estimated to grow at a CAGR of 5.70% during the forecast period.
Browse the full “ Blood Plasma Fractionation Market Size, Share, Growth Analysis Report By Product (Albumin, Immunoglobulin, Coagulation Factors, Protease Inhibitors, Others), By Application (Immunology & Neurology, Hematology, Critical Care, Pulmonology, & Others), By End-User (Hospitals & Clinics, Research Laboratories, & Academic Institutes), and By Region-Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecast 2022 – 2028" report at https://www.fnfresearch.com/blood-plasma-fractionation-market
The increased use of immunoglobulins and alpha-1-antitrypsin in various fields of medicine around the world also contributes to the market's expansion for blood plasma fractionation. Increasing numbers of plasma collection facilities around the world are a significant component of the market's expansion. The expansion of the blood plasma fractionation market is also fuelled by favorable government support for raising awareness about the use of plasma-derived products. The growth potential of emerging economies is anticipated to produce profitable chances for market expansion. The expensive cost of products made from plasma limits market expansion.
Segmental Overview
The Global Blood Plasma FractionationMarket is segregated based on product, application, end-user, and region. Based on product, the market is categorized into Albumin, Immunoglobulin, Coagulation Factors, Protease Inhibitors, and Others. Among these, the immunoglobulin segment will dominate the market in 2021. Based on application, the market is classified into Immunology & Neurology, Hematology, Critical Care, Pulmonology, & Others. Over the forecast period, the immunology & neurology segment is expected to develop at the fastest rate in 2021. Based on end-user, the market is classified into Hospitals & Clinics, Research Laboratories, & Academic Institutes. The hospitals & clinics segment will dominate the market in 2021.
Regional Overview
North America dominates the Global Blood Plasma FractionationMarket because of its well-established healthcare industry in 2021. The supremacy is due to a combination of a highly established infrastructure and an increase in research and development in the area. It is anticipated that favorable government regulations and recently FDA-approved medicines would further accelerate market expansion. In 2021, the Asia Pacific Blood Plasma FractionationMarket is expected to be the fastest-growing regional market.
Rising consumption of plasma-derived products, strategic developments made by regional businesses, the presence of top players, contract fractionation agreements between nations, and initiatives to expand the use of plasma and its fractionation are the main factors propelling the growth of the Asia Pacific blood plasma fractionation market. The market for plasma fractionation in the region is anticipated to increase due to a surge in leading manufacturers' attention to increasing their geographic presence in developing Asia-Pacific nations to secure a significant market share.
Report Scope
Report Attribute |
Details |
Market Size in 2021 |
USD 28.1 Billion |
Projected Market Size in 2028 |
USD 39.2 Billion |
CAGR Growth Rate |
5.70% CAGR |
Base Year |
2021 |
Forecast Years |
2022-2028 |
Key Market Players |
CSL (Australia), Grifols, S.A. (Spain), Shire (U.S.), Octapharma AG (Switzerland), (China), KabaFusion, Kedrion S.P.A (Italy), Japan Blood Products Organization (Japan), Emergent BioSolutions (U.S.), LFB (France), Biotest AG (Germany), Sanquin (Netherlands), and Others |
Key Segment |
By Product, Application, End-user, and Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Competitive Landscape
Key players functioning in the global Blood Plasma Fractionation market include CSL (Australia), Grifols, S.A. (Spain), Shire (US), Octapharma AG (Switzerland), Kedrion S.P.A (Italy), Japan Blood Products Organization (Japan), Emergent BioSolutions (US), LFB (France), Biotest AG (Germany), Sanquin (Netherlands), Intas Pharmaceuticals Ltd. (India), Bharat Serum Vaccines Limited (India), China Biologic Products Holdings Inc. (China), GC Pharma (Korea), Bio Products Ltd. (UK), Shanghai Raas Blood Products Co., Ltd. (China), SK Plasma (Korea), Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China), KabaFusion (US), Centurion Pharma (Istanbul), ADMA Biologics, Inc. (the US), Fusion Healthcare (India), Hemarus Therapeutics Limited (India), PlasmaGen BioSciences Pvt. Ltd. (India), and Virchow Biotech Private Limited (India).
Recent developments:
- March 2020- The first healthcare facility to try plasma treatment for COVID-19 was one of the hospitals in Houston, Texas, in the United States. Convalescent serum therapy is the name of the therapeutic approach.
- February 2019- One of the top players in the Japanese biopharmaceutical market, Shire, was successfully acquired by Takeda Pharmaceutical Company Limited.
The Global Blood Plasma Fractionation Market is segmented as follows:
By Product
- Albumin
- Immunoglobulin
- Coagulation Factors
- Protease Inhibitors
- Others
By Application
- Immunology & Neurology
- Hematology
- Critical Care
- Pulmonology
- Others
By End-user
- Hospitals & Clinics
- Research Laboratories
- Academic Institutes
By Region
- North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com
